For the roughly 30% of glioblastoma patients whose tumors are deemed surgically unreachable, treatment options are devastatingly limited. A minimally invasive thermal ablation technique has long been theorized as a cytoreductive bridge, but until now it lacked rigorous randomized evidence — making even a prematurely stopped trial worth examining closely.
The EMITT trial, conducted across seven Dutch neurosurgical centers, randomized 26 adults with unresectable glioblastoma 1:1 to standard-of-care following biopsy alone versus biopsy combined with same-session MRI-guided laser interstitial thermal therapy (LITT). The intervention group demonstrated a median overall survival of 7.8 months compared with 4.8 months in controls — a three-month difference that, while clinically suggestive, carries wide confidence intervals given the sample. Quality-of-life scores at five months, measured via the QLQ-C30 instrument, were numerically similar between arms (81 vs. 77 summary score), suggesting LITT did not meaningfully compromise functional wellbeing in the near term. Critically, the trial was terminated early after funding withdrawal driven by slow enrollment, leaving it substantially underpowered for its co-primary endpoints.
Glioblastoma remains one of oncology's most resistant targets, with median survival under 15 months even in operable, optimally treated cases. LITT's proposed mechanism — focal thermal ablation disrupting the blood-brain barrier and potentially enhancing adjuvant therapy uptake — has biological plausibility, and small retrospective series have hinted at benefit. However, this trial's 26-patient intention-to-treat population is insufficient to distinguish a genuine survival signal from random variation or selection effects. The non-blinded design and early termination further limit interpretability. That said, the observed 3-month survival difference is proportionally meaningful in a disease where months matter profoundly. This work is best classified as hypothesis-generating rather than practice-changing, and it underscores the urgent need for adequately powered, well-funded randomized trials in this neglected surgical subgroup.